Abstract
Physiological activation of PI3Kα is brought about by the release of the inhibition by p85 when the nSH2 binds the phosphorylated tyrosine of activated receptors or their substrates. Oncogenic mutations of PI3Kα result in a constitutively activated enzyme that triggers downstream pathways that increase tumor aggressiveness and survival. Structural information suggests that some mutations also activate the enzyme by releasing p85 inhibition. Other mutations work by different mechanisms. For example, the most common mutation, His1047Arg, causes a conformational change that increases membrane association resulting in greater accessibility to the substrate, an integral membrane component. These effects are examples of the subtle structural changes that result in increased activity. The structures of these and other mutants are providing the basis for the design of isozyme-specific, mutation-specific inhibitors for individualized cancer therapies.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Amzel LM et al (2008) Structural comparisons of class I phosphoinositide 3-kinases. Nat Rev Cancer 8:665–669
Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296(5573):1655–1657
Carson JD et al (2008) Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. Biochem J 409(2):519–524
Escobedo JA et al (1991) cDNA cloning of a novel 85 kd protein that has SH2 domains and regulates binding of PI3-kinase to the PDGF beta-receptor. Cell 65(1):75–82
Fu Z et al (2004) The iSH2 domain of PI 3-kinase is a rigid tether for p110 and not a conformational switch. Arch Biochem Biophys 432(2):244–251
Huang CH et al (2007) The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 318(5857):1744–1748
Huang CH et al (2008) Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha. Cell Cycle 7:1151–1156
Jimenez C et al (1998) Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. EMBO J 17(3):743–753
Kalinsky K et al (2009) PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15(16):5049–5059
Lai YL et al (2008) PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol 15(4):1064–1069
Lerma E et al (2008) Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas. Virchows Arch 453(2):133–139
Mandelker D et al (2009) A frequent kinase domain mutation that changes the interaction between PI3Ka and the membrane. PNAS 8(9):665–669
Miled N et al (2007) Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317(5835):239–242
Otsu M et al (1991) Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp 60c-src complexes, and PI3-kinase. Cell 65(1):91–104
Parsons DW et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812
Samuels Y et al (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670):554
T.C.G.A.R. (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061–1068
Vanhaesebroeck B, Waterfield MD (1999) Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 253(1):239–254
Vogt PK et al (2007) Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci 32(7):342–349
Wellcome Trust Sanger Institute (2009) Catalogue of Somatic Cancer Mutations
Yu J et al (1998a) Regulation of the p85/p110 phosphatidylinositol 3′-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol 18(3):1379–1387
Yu J, Wjasow C, Backer JM (1998b) Regulation of the p85/p110alpha phosphatidylinositol 3′-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains. J Biol Chem 273(46): 30199–30203
Zhao L, Vogt PK (2008a) Class I PI3K in oncogenic cellular transformation. Oncogene 27(41):5486–5496
Zhao L, Vogt PK (2008b) Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA 105(7):2652–2657
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Gabelli, S.B., Huang, CH., Mandelker, D., Schmidt-Kittler, O., Vogelstein, B., Amzel, L.M. (2010). Structural Effects of Oncogenic PI3Kα Mutations. In: Rommel, C., Vanhaesebroeck, B., Vogt, P. (eds) Phosphoinositide 3-kinase in Health and Disease. Current Topics in Microbiology and Immunology, vol 347. Springer, Berlin, Heidelberg. https://doi.org/10.1007/82_2010_53
Download citation
DOI: https://doi.org/10.1007/82_2010_53
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-14815-6
Online ISBN: 978-3-642-14816-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)